SCHEMBL6779702

SCHEMBL6779702

COC(=O)C(CC1CO1)NS(=O)(=O)c1ccc(-c2ccc(Cl)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 10/20 0.52
ADAMTS5 Q9UNA0 1/20 0.52
MMP9 P14780 6/20 0.47
MMP1 P03956 2/20 0.47
MMP3 P08254 2/20 0.47
MMP7 P09237 2/20 0.47
MMP13 P45452 2/20 0.47
MMP8 P22894 2/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MMP14 P50281 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6769905 0.91 MMP2 (0.53) MMP2ADAMTS5MMP9MMP1MMP3
SCHEMBL6774654 0.89 MMP2 (0.53) MMP2MMP9MMP1MMP3MMP7
SCHEMBL6768565 0.89 MMP2 (0.53) MMP2MMP9MMP1MMP3MMP7
SCHEMBL6769986 0.78 MMP2 (0.52) MMP2ADAMTS5MMP9MMP1MMP3
SCHEMBL7493868 0.78 MMP2 (0.52) MMP2ADAMTS5MMP9MMP1MMP3
SCHEMBL10076123 0.78 MMP2 (0.50) MMP2ADAMTS5MMP9MMP1MMP3
SCHEMBL3065763 0.78 MMP2 (0.50) MMP2ADAMTS5MMP9MMP1MMP3
SCHEMBL2381380 0.75 LMNA (0.54) MMP2ADAMTS5MMP9MMP1MMP3
SCHEMBL27455490 0.75 LMNA (0.54) MMP2ADAMTS5MMP9MMP1MMP3
SCHEMBL3015042 0.72 MMP2 (0.71) MMP2ADAMTS5MMP9MMP1MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6762198-B2 SUCH AS 2-((4'-METHOXY-(1,1'-BIPHENYL)-4-YL)-SULFONYL)-AMINO-3-(2-PHENOXYMETHYL -(1,3)DIOXAN-2-YL)PROPIONIC ACID THE PROCTER & GAMBLE COMPANY 2004-07-13 US disclosed
US-20030225074-A1 Dihetero-substituted metalloprotease inhibitors THE PROCTER & GAMBLE COMPANY 2003-12-04 US disclosed
US-6566381-B1 For therapy of arthritis, cancer, cardiovascular disorder, skin disorder, ocular disorder, inflammation and gum disease THE PROCTER & GAMBLE COMPANY 2003-05-20 US disclosed
EP-1165530-A2 DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2002-01-02 EP disclosed
WO-2000051993-A2 DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2000-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225074-A1 Dihetero-substituted metalloprotease inhibitors ADAM9, ADAM17, ADAM8 MMP2 10/4885ADAMTS5 26/4885MMP9 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.